DDReg Pharma Pvt Ltd

Home
India
Gurugram
DDReg Pharma Pvt Ltd

Incepted in the year 2009, the company is involved in a wide variety of regulatory & drug safety assignments which span across global markets.

DDReg is a global life sciences consulting firm specializing in regulatory affairs, pharmacovigilance, and quality services, accelerating product registrations and ensuring compliance through smart RegTech and deep industry expertise. Rich subject matter expertise gets combined with cutting edge technology solutions providing end to end support across pharma value chain. The company supports globa

l pharmaceutical organizations for their needs to address regulatory challenges pertaining to Biologicals, Complex formulations, INDs, NDAs and Generics, Consumer Healthcare products and Medical Devices, in highly regulated markets as well as in complex emerging markets. The services portfolio includes Document management, Dossier support, pre-Approval and Post MA regulatory support, Submission management, Regulatory Intelligence, Regulatory Strategies, Feasibility Studies, Dossier compilation, submissions, Agency follow ups and approvals. The Drug Safety Vertical supports global organizations to manage their worldwide Safety Obligations by way of Case Management, Aggregate Reporting, Safety Compliances, Signal Detection and Risk Management. Functional and Operational Excellence are manifested through Strong Quality Management System, and Efficient Project Management.

10/08/2026

Jordan’s PIC/S membership is an important development for GMP compliance and global regulatory alignment.

Our latest article explores what this could mean for pharmaceutical manufacturers and international market access.

📖 Read more: Full article
https://resource.ddregpharma.com/blogs/jordan-pics-membership-gmp-compliance/

09/08/2026

Regulatory science continues to evolve with the FDA's latest QSP guidance for CDER.

Quantitative Systems Pharmacology (QSP) is helping improve first-in-human dose selection by combining computational modeling with biological and pharmacological insights.

Our latest article explores how this guidance may influence clinical development and regulatory decision-making for high-risk biologics.

Read the full article:
🔗 https://resource.ddregpharma.com/blogs/fda-qsp-guidance-for-cder/

08/08/2026

The future of pharmaceutical regulation goes beyond compliance—it also includes sustainability.

The WHO Greener Pharmaceuticals Initiative highlights the growing importance of integrating environmental responsibility into pharmaceutical development, manufacturing, and regulatory strategy.

Our latest article explores how sustainability is influencing global regulatory expectations and what it means for pharmaceutical companies.

Read the full article:
🔗 https://resource.ddregpharma.com/insights/who-greener-pharmaceuticals-initiative/

How do you see sustainability shaping the future of pharmaceutical regulation?

07/08/2026

Artificial Intelligence is reshaping Regulatory Affairs by supporting regulatory intelligence, literature reviews, and document analysis.

Yet successful regulatory decisions continue to depend on scientific expertise, strategic thinking, and human oversight.

Our latest article explores where AI adds real value—and where human expertise remains irreplaceable.

Read more: https://resource.ddregpharma.com/blogs/ai-in-regulatory-affairs/

06/08/2026

Entering Brazil is the beginning of the regulatory journey, not the end.

Market authorization for veterinary products is only the first milestone.

Post-market surveillance, GMP compliance, pharmacovigilance, and lifecycle
regulatory updates continue long after approval. Sustainable market access depends on
continuous compliance, not a one-time submission.

Partner with DDReg to navigate Brazil's veterinary regulatory lifecycle with confidence, from market entry to ongoing compliance.

Visit: https://www.ddregpharma.com/industry/veterinary

05/08/2026

Generic manufacturers don't have to rely on ANDA alone.

Some products simply fall outside the traditional ANDA pathway, making approvals more challenging than expected.

The FDA's 505(b)(2) pathway offers a strategic alternative, enabling manufacturers to leverage existing safety and efficacy data, reduce development burdens, and bring differentiated products to market faster.

Discover how a well-planned ANDA strategy for 2026 can help unlock new opportunities and gain a competitive edge.

Read the complete guide below.
https://www.ddregpharma.com/

04/08/2026

From lab to livestock, every veterinary medicine in Germany follows a strict regulatory pathway.

Approval begins with dossier preparation, followed by submission to BVL.
Depending on scope, review is conducted via EMA or national procedures, including scientific evaluation of quality, safety, and efficacy.

If approved under EU Regulation (EU) 2019/6, the product enters the market but remains under continuous pharmacovigilance and safety monitoring.

Simplify EU veterinary regulatory pathways with DDReg:

https://www.ddregpharma.com/industry/veterinary

03/08/2026

Behind every approved medicine, biologic, or medical device is a regulatory dossier built on thousands of interconnected documents—each requiring scientific accuracy, technical consistency, and regulatory compliance.

At DDReg Pharma, we help transform regulatory complexity into structured, submission-ready dossiers that support efficient global submissions and long-term lifecycle compliance.

From administrative documentation and CMC to clinical summaries, labelling, risk management, and lifecycle maintenance, we deliver end-to-end regulatory dossier solutions with precision and confidence.

Because successful submissions aren't just about documentation—they're about delivering the right information, in the right format, at the right time.

For more : https://www.ddregpharma.com/solutions/regulatory-affairs

02/08/2026

Successfully entering the Nigerian market requires more than submitting an application. Understanding NAFDAC's regulatory requirements, import compliance, and registration process is essential for a smooth approval journey.

Our latest blog provides a comprehensive guide covering:
NAFDAC drug registration process
Documentation and approval requirements
Import compliance considerations
Market access strategies
Practical insights to help accelerate your registration journey

Whether you're launching a new product or expanding into Nigeria, staying informed can help minimize delays and ensure regulatory compliance.

📖 Read the full blog and prepare your products for successful market entry.
https://resource.ddregpharma.com/blogs/nafdac-drug-registration-nigeria/

01/08/2026

Healthy lungs are fundamental to healthy lives. Yet millions of people worldwide continue to be affected by preventable and manageable respiratory diseases.

On World Lung Day, we are reminded that awareness, early diagnosis, preventive healthcare, and access to quality medicines are essential to improving respiratory health outcomes. Every step toward stronger healthcare systems, scientific innovation, regulatory excellence, and patient education contributes to protecting lung health and enhancing quality of life.

At DDReg, we remain committed to supporting the development and regulatory pathways that help bring safe, effective, and high-quality healthcare solutions to patients around the world.

Together, let us build awareness today for healthier tomorrow.

For More:- https://www.ddregpharma.com/

Address

Units 444-451, Tower B2, 4-floor Spaze-I-Tech Park, Sector 49, Sohna Road
Gurugram
122018

Telephone

+911244361505-06

Website

https://www.ddregpharma.com/, https://resource.ddregpharma.com/, https://x.com/DDRegPharma, https://www.linkedin.com/com

Alerts

Be the first to know and let us send you an email when DDReg Pharma Pvt Ltd posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to DDReg Pharma Pvt Ltd:

Want your practice to be the top-listed Clinic in Gurugram?